Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for NCGC00024978-05

    Client Email Product

    NCGC00024978-05

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    0

    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    0

    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    19
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson
    Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson

    https://www.businesswire.com/news/home/20230818971170/en

    BUSINESSWIRE
    18 Aug 2023
    Share Share
    Can-Fite Receives USFDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
    Can-Fite Receives USFDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

    https://www.businesswire.com/news/home/20230629172102/en

    BUSINESSWIRE
    29 Jun 2023
    Share Share
    Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Companies
    Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Companies

    https://www.businesswire.com/news/home/20230316005101/en

    BUSINESSWIRE
    16 Mar 2023
    Share Share
    Can-Fite Submits Market Registration Plan to EMA for Piclidenoson
    Can-Fite Submits Market Registration Plan to EMA for Piclidenoson

    https://www.businesswire.com/news/home/20230110005515/en

    BUSINESSWIRE
    10 Jan 2023
    Share Share
    Can-Fite: New PIII Psoriasis Data Showing Superior Safety & Improved Efficacy
    Can-Fite: New PIII Psoriasis Data Showing Superior Safety & Improved Efficacy

    https://www.businesswire.com/news/home/20220912005019/en

    BUSINESSWIRE
    12 Sep 2022
    Share Share
    Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis
    Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis

    https://www.businesswire.com/news/home/20220817005358/en

    BUSINESSWIRE
    17 Aug 2022
    Share Share
    Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in Psoriasis
    Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in Psoriasis

    https://www.businesswire.com/news/home/20220711005256/en

    BUSINESSWIRE
    11 Jul 2022
    Share Share
    Can-Fite to Present at Dermatology Drug Development Summit Europe
    Can-Fite to Present at Dermatology Drug Development Summit Europe

    https://www.businesswire.com/news/home/20220328005011/en

    BUSINESSWIRE
    28 Mar 2022
    Share Share
    Can-Fite CEO to Present Namodenoson’s Clinical Trial Data
    Can-Fite CEO to Present Namodenoson’s Clinical Trial Data

    https://www.businesswire.com/news/home/20211026005086/en

    BUSINESSWIRE
    26 Oct 2021
    Share Share
    Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance
    Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance

    https://www.businesswire.com/news/home/20200715005283/en/Can-Fite-Completes-Phase-II-COVID-19-Protocol-Based

    BUSINESSWIRE
    15 Jul 2020
    Share Share
    Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance
    Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance

    https://www.businesswire.com/news/home/20200715005283/en

    BUSINESSWIRE
    14 Jul 2020
    Share Share
    Applied Biology and Kintor to Collaborate on the use of Proxalutamide
    Applied Biology and Kintor to Collaborate on the use of Proxalutamide

    https://www.businesswire.com/news/home/20200714005921/en

    BUSINESSWIRE
    14 Jul 2020
    Share Share
    Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Ph II
    Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Ph II

    https://www.businesswire.com/news/home/20200609005353/en

    BUSINESSWIRE
    09 Jun 2020
    Share Share
    Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson
    Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson

    https://www.businesswire.com/news/home/20200515005117/en

    BUSINESSWIRE
    15 May 2020
    Share Share
    Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Enrollment
    Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Enrollment

    https://www.businesswire.com/news/home/20200413005191/en

    BUSINESSWIRE
    13 Apr 2020
    Share Share
    Can-Fite Updates on Milestone for its Ph III Rheumatoid Arthritis Piclidenoson
    Can-Fite Updates on Milestone for its Ph III Rheumatoid Arthritis Piclidenoson

    https://www.biospace.com/article/releases/can-fite-updates-on-clinical-milestone-for-its-phase-iii-rheumatoid-arthritis-study-with-piclidenoson-drugs-combating-rheumatoid-arthritis-are-currently-introduced-for-the-treatment-of-the-coronavirus/

    BIOSPACE
    05 Mar 2020
    Share Share
    Can-Fite is Filing Drug Safety Update-Ph II & Ph III Namodenoson & Piclidenoson
    Can-Fite is Filing Drug Safety Update-Ph II & Ph III Namodenoson & Piclidenoson

    https://www.businesswire.com/news/home/20200303005502/en

    BUSINESSWIRE
    03 Mar 2020
    Share Share
    Can-Fite Completes 50% Patient Enrollment in PhIII Rheumatoid Arthritis Study
    Can-Fite Completes 50% Patient Enrollment in PhIII Rheumatoid Arthritis Study

    https://markets.businessinsider.com/news/stocks/can-fite-completes-50-patient-enrollment-in-phase-iii-rheumatoid-arthritis-study-implements-interim-analysis-1028867348

    BUSINESSINSIDER
    03 Feb 2020
    Share Share
    Drugs with MOA Utilized by Namodenoson Recommended to Combat Liver Cancer
    Drugs with MOA Utilized by Namodenoson Recommended to Combat Liver Cancer

    https://www.businesswire.com/news/home/20180702005387/en/Drugs-Mechanism-Action-Utilized-Namodenoson-Recommended-Leading

    BUSINESSWIRE
    02 Jul 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search